Clinical Review Fortnightly review

Ductal carcinoma in situ of the breast

BMJ 1998; 317 doi: https://doi.org/10.1136/bmj.317.7160.734 (Published 12 September 1998) Cite this as: BMJ 1998;317:734
  1. Melvin J Silverstein (melsilver9@aol.com), medical director
  1. The Breast Center, 14624 Sherman Way, Van Nuys, CA 91405, USA
  1. Correspondence to: Dr M J Silverstein, University of Southern California, Norris Cancer Center, 1441 Eastlake Avenue, Room 7415A, Los Angeles, CA 90033, USA

    Ductal carcinoma in situ is a proliferation of malignant epithelial cells within the ductolobular system of the breast that show no light microscopic evidence of invasion through the basement membrane into the surrounding stroma (fig 1). Several forms of histological architecture are recognised, the most common of which are comedo, cribriform, solid, micropapillary, and papillary.

    Until recently, ductal carcinoma in situ was a relatively uncommon disease, representing only about 1% of all newly diagnosed cases of breast cancer.1 It was usually regarded as a single disease with a single treatment, namely, mastectomy. Most patients presenting with ductal carcinoma in situ had symptoms—a palpable mass or discharge from the nipple. During the past decade, as mammography has become more widely used and technically better, the number of new cases has increased dramatically. Most patients now present with lesions that are not palpable and are clinically occult. Furthermore, the notion of ductal carcinoma in situ as a single disease has evaporated. It is now well recognised as a heterogeneous group of lesions with a diverse malignant potential. As our understanding of the disease has evolved and the range of treatment options has widened, the process of making decisions about management has become more complex and controversial. Ductal carcinoma in situ has become so common and so confusing that the first textbook devoted solely to the disorder was not published until 1997.2

    Summary points

    • Cases of ductal carcinoma in situ have increased appreciably as mammography has improved and pathologists are becoming more familiar with minimal lesions

    • Ductal carcinoma in situ is a heterogeneous group of lesions, and no singleapproach to treatment is suitable for all patients

    • Although radiotherapy is recommended after lumpectomy, this may not be necessary in all subgroups of patients

    • The Van Nuys prognostic index combines scores for three prognostic factors; …

    View Full Text

    Sign in

    Log in through your institution

    Free trial

    Register for a free trial to thebmj.com to receive unlimited access to all content on thebmj.com for 14 days.
    Sign up for a free trial

    Subscribe